本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次解除限售股份的来源 2015 年 11 月 27 日，创新医疗管理股份有限公司（以下简称"公司"）收 到中国证券监督管理委员会《关于核准千足珍珠集团股份有限公司向上海康瀚投 资管理中心（有限合伙）等发行股份购买资产并募集配套资金的批复》（证监许 可【2015】2696 号），核准公司向上海康瀚投资管理中心（有限合伙）（以下 简称"康瀚投资"）等发行 127,334,463 股新股购买相关资产，其中，向康瀚投 资发行 46,080,473 股，新增股份上市日期为 2016 年 2 月 15 日。 证券代码：002173 证券简称：创新医疗 公告编号：2026-009 创新医疗管理股份有限公司 2026 年 3 月 23 日，公司接到中国证券登记结算有限责任深圳分公司的通知， 韩猛所持有的公司 4,275,513 股股票已被司法强制解限，上市流通日为 2026 年 3 月 23 日。 1 / 2 关于股东所持公司部分限售股份解除限售的公告 康瀚投资作为齐齐哈尔建华医院有限责任公司的业绩承诺人，业绩补偿义务 未 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6] Core Views - The medical and biological sector experienced a decline of 2.77% this week, ranking 8th among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index fell by 2.19%, indicating that the medical sector underperformed by 0.59 percentage points [1] - The report highlights a new policy from the Ministry of Commerce aimed at promoting international medical tourism, which is expected to enhance the appeal of private hospitals by allowing them to tap into high-value services such as high-end physical examinations and cosmetic surgery [4] - The medical services sector's current Price-to-Earnings (PE) ratio is 30.77X, with a Price-to-Book (PB) ratio of 3.12X, reflecting a slight decrease from the previous week [3] Summary by Sections Industry Performance - The medical services sector index closed at 6472.58 points, down 4.32% for the week, while the overall medical and biological sector index fell by 2.77% [1][22] - Notable performers in the medical services sector included WuXi AppTec (0.0%) and Aier Eye Hospital (-1.8%), while companies like Sanbo Brain Science and Proprius saw significant declines of -20.7% and -16.8%, respectively [2][22] Valuation Metrics - The medical services sector's PE ratio (ttm) is 30.77X, with a one-year maximum of 41.13X and a minimum of 28.46X. The current PB ratio is 3.12X, with a one-year maximum of 4.00X and a minimum of 2.48X [3] Investment Suggestions - The report suggests focusing on high-growth areas such as ADC CDMO and the peptide CDMO in the weight loss drug supply chain, with companies like WuXi AppTec and Aier Eye Hospital recommended for their growth potential [5] - It also highlights the potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [5]

Core Viewpoint - The article highlights the recent surge in brain-computer interface (BCI) concept stocks, particularly following the approval of a groundbreaking BCI medical device by the National Medical Products Administration of China, which is set to enhance the quality of life for patients with quadriplegia [1][4]. Group 1: Market Reaction - On March 13, brain-computer interface concept stocks experienced significant movement, with companies like Innovation Medical and Sanbo Brain Science seeing their shares rise nearly 10% [1]. - Innovation Medical's stock price increased by 5.55%, closing at 31.40, with a trading volume of 640,200 shares and a total transaction amount of 1.96 billion [2]. Group 2: Product Approval and Features - The National Medical Products Administration approved the registration application for a novel implanted brain-computer interface system by Borekan Medical Technology, marking the first global launch of such a medical device [4]. - The product includes components such as an implanted brain-computer interface, brain electrode kit, signal transceiver, pneumatic glove, surgical tool kit, and software for decoding brain signals and clinical management [4]. - It is designed for patients aged 18 to 60 with cervical spinal cord injuries, specifically those classified as A to C on the ASIA scale, who have stable conditions for at least six months and cannot perform hand grasping [4].

证券代码：002173 证券简称：创新医疗 公告编号：2026-008 创新医疗管理股份有限公司 二、担保进展情况 近日，公司与北京银行诸暨支行签署了《保证合同》（合同编号： RTL000334601），具体内容如下： 1、债权人：北京银行股份有限公司绍兴诸暨支行 2、保证人：创新医疗管理股份有限公司 3、主债务人：浙江鸿润医药有限公司 4、被担保的主合同： （1）主合同为北京银行与主债务人已经或即将订立的名称为《借款合同》 的合同及其有效修订与补充。 （2）本合同项下的被担保主债权（担保范围）为主合同项下北京银行（及 按主合同约定取得债权人地位的北京银行股份有限公司其他分支机构）的全部债 权，包括主债权本金人民币壹仟万元以及利息、罚息、复利、违约金、损害赔偿 金、实现债权和担保权益的费用（包括但不限于诉讼/仲裁费用、评估/鉴定/拍 卖等处置费用、律师费用、调查取证费用、差旅费及其他合理费用）等其他款项。 关于为鸿润医药提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次担保情况概述 创新医疗管理股份有限公司（以下简称"公司"）于 20 ...

Core Viewpoint - The medical services sector experienced a slight increase of 0.32% on February 27, with Innovative Medical leading the gains [1] Group 1: Market Performance - On the same day, the Shanghai Composite Index closed at 4162.88, up by 0.39% [1] - The Shenzhen Component Index closed at 14495.09, showing a minor decline of 0.06% [1] Group 2: Capital Flow - The medical services sector saw a net inflow of 239 million yuan from main funds, while retail investors experienced a net outflow of 208 million yuan [1] - Speculative funds recorded a net outflow of 31.32 million yuan [1]

Core Insights - The China Securities Medical and Medical Device Innovation Index (931484) has seen a slight increase of 0.31%, with notable gains from stocks such as Huitai Medical (+6.20%) and Yingke Medical (+4.17%) [1] - The National Medical Products Administration (NMPA) reported that in 2025, it received 457 applications for special approval of innovative medical devices, with 104 approved for special review and 26 out of 38 priority applications granted [1] Group 1: Market Performance - The Medical Innovation ETF (516820) rose by 0.28%, with the latest price at 0.36 yuan [1] - The top ten weighted stocks in the China Securities Medical and Medical Device Innovation Index account for 63.9% of the index, including companies like WuXi AppTec and Mindray Medical [2] Group 2: Investment Strategy - Huafu Securities emphasizes a continued focus on the pharmaceutical technology sector, highlighting three main areas for 2026: revenue and performance realization, unexpected business development outcomes, and cutting-edge technology platforms [2] - In the medical device sector, the focus is on inventory replenishment and bidding for surgical robots and endoscopes, as well as innovative consumables benefiting from centralized procurement [2] - The central economic work conference has indicated a shift towards domestic demand, suggesting that companies related to domestic medical needs may experience a turning point [2]

Core Viewpoint - Innovation Medical (002173) shows a mixed financial performance with a slight decline in revenue but significant growth in net profit for the first three quarters of 2025 [3]. Group 1: Stock Performance - As of February 13, 2026, Innovation Medical's stock closed at 29.46 yuan, up 1.62%, with a turnover rate of 10.8% and a trading volume of 449,500 hands, resulting in a transaction amount of 1.319 billion yuan [1]. - On February 13, the net inflow of main funds was 85.61 million yuan, accounting for 6.49% of the total transaction amount, while retail investors saw a net outflow of 111 million yuan, representing 8.45% of the total transaction amount [1]. Group 2: Financing and Margin Trading - In the financing and margin trading data, on the same day, the financing buy amounted to 111 million yuan, while financing repayment was 123 million yuan, resulting in a net repayment of 12.14 million yuan [2]. - The margin trading data indicates no shares were sold or repaid, with a remaining margin of 13,700 shares and a margin balance of 403,600 yuan [2]. Group 3: Financial Performance - For the first three quarters of 2025, Innovation Medical reported a main revenue of 597 million yuan, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.7244 million yuan, showing a year-on-year increase of 116.97% [3]. - The third quarter alone saw a main revenue of 196 million yuan, down 3.16% year-on-year, but the net profit attributable to shareholders surged by 236.15% to 16.0857 million yuan [3]. - The company reported a debt ratio of 17.84%, investment income of 29.5055 million yuan, financial expenses of 605,500 yuan, and a gross profit margin of 10.08% [3].

Core Viewpoint - Micron Heart Technology-B (02160) saw a significant increase of over 6%, currently trading at 0.84 HKD with a transaction volume of 8.5992 million HKD, following the announcement of its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN entering the special review process by the National Medical Products Administration (NMPA) [1] Group 1 - The NMPA's Medical Device Technology Review Center has published the review results for the special application of innovative medical devices, indicating a potential approval for the TILEN/EYLEN ICD [1] - TILEN/EYLEN is expected to be the first domestically approved ICD with independent intellectual property rights that is safe for use under magnetic resonance conditions [1]

Group 1 - The core point of the article is that MicroPort Cardiac Rhythm Management (微创心通-B) has seen its stock price increase by over 6% following the announcement of a significant regulatory milestone for its new generation implantable cardioverter-defibrillator (ICD) [1] - As of the time of reporting, the stock price rose by 6.33% to HKD 0.84, with a trading volume of HKD 8.5992 million [1] - The National Medical Products Administration (NMPA) has indicated its intention to approve the TILEN/EYLEN ICD for entry into the special review process, which is part of the NMPA's green channel for innovative medical devices [1] Group 2 - The TILEN/EYLEN ICD is expected to be the first domestically approved ICD with independent intellectual property rights that is safe for use under magnetic resonance conditions [1]

Group 1 - The core point of the article is that MicroPort CardioFlow-B (02160.HK) has received a favorable review from the NMPA for its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN, which is expected to be the first domestically approved MRI-safe ICD with independent intellectual property rights [1] - The stock closed at HKD 0.79, up 2.6% with a trading volume of 8.472 million shares and a turnover of HKD 6.6143 million as of February 13, 2026 [1] - The stock has a market capitalization of HKD 4.902 billion and ranks 9th in the medical device II industry [1] Group 2 - MicroPort CardioFlow-B has a Return on Equity (ROE) of 0.24%, which is significantly higher than the industry average of -4.82%, ranking 17th out of 28 [2] - The company's operating revenue is HKD 368 million, compared to the industry average of HKD 1.201 billion, ranking 19th out of 28 [2] - The gross profit margin of MicroPort CardioFlow-B is 70.24%, which is above the industry average of 53.75%, ranking 6th out of 28 [2]